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Essentials
• A residual factor VIII synthesis is likely to be protective towards inhibitor (INH) development.
• Mutation type-inhibitor risk association was explored in 231 patients with severe hemophilia A.
• A 2-fold increase in INH development for in silico null vs. non-null mutations was found.
• A 3.5-fold increase in INH risk for antigen negative vs.
antigen positive mutations was found.
Summary. Background: The type of F8 mutation is the main predictor of inhibitor development in patients with severe hemophilia A. Mutations expected to allow residual synthesis of factor VIII are likely to play a protective role against alloantibody development by inducing immune tolerance. According to the expected full or partial impairment of FVIII synthesis, F8 variants are commonly classified as null and non-null. Objectives: To explore the mutation type-inhibitor risk association in a cohort of 231 patients with severe hemophilia A enrolled in the Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET) randomized trial. Methods: The genetic defects in these patients, consisting of inversions of intron 22 (n = 110) and intron 1 (n = 6), large deletions (n = 16), and nonsense (n = 38), frameshift (n = 28), missense (n = 19) and splicing (n = 14) variants, of which 34 have been previously unreported, were reclassified according to two additional criteria: the functional effects of missense and splicing alterations as predicted by multiple in silico analyses, and the levels of FVIII antigen in patient plasma. Results: A two-fold increase in inhibitor development for in silico null mutations as compared with in silico non-null mutations (hazard ratio [HR] 2.08, 95% confidence interval [CI] 0.84-5.17) and a 3.5-fold increase in inhibitor development for antigen-negative mutations as compared with antigen-positive mutations (HR 3.61, 95% CI 0.89-14.74] were found. Conclusions: Our findings confirm an association between the synthesis of minute amounts of FVIII and inhibitor protection, and
Introduction
Hemophilia A (OMIM #306700), which is one of the most common congenital coagulopathies, is characterized by variations in the frequency and severity of bleeding episodes related to the residual amount of factor VIII coagulant (FVIII:C) activity in patient plasma [1] . The current therapeutic approach for hemophilia A is aimed at correcting the inherited deficiency of FVIII by the administration of plasma-derived or recombinant FVIII products. This replacement therapy improves the management of the hemorrhagic diathesis, reduces mortality, and improves the quality of life for patients [2] .
A serious complication of this therapy is the development of inhibitors (i.e. neutralizing alloantibodies against FVIII), which nullify treatment benefits. The degree and severity of FVIII inactivation depend on the level of inhibitor present (> 5 Bethesda units [BU] ) [1] . In these cases, hemostasis can be achieved only by using FVIII-bypassing agents [3] , with a high cost of treatment. Inhibitor eradication is successful in approximately two-thirds of cases by means of immune tolerance induction, but with exorbitant costs [4] .
The inhibitor incidence is associated with the degree of FVIII deficiency, as it occurs in only 3-13% of patients with mild and moderate hemophilia A, but in > 30% (of whom 60% have high titers) of those with severe hemophilia A [5] . The residual amount of endogenous FVIII offers a likely explanation for this difference, through the induction of natural immune tolerance [6] . Furthermore, established determinants of inhibitor formation are the patient's genetic background, and environmental factors [7] [8] [9] [10] . Among them, the type of mutation in F8 is the strongest risk factor for inhibitor development [11, 12] .
A wide spectrum of defects in F8 are associated with severe hemophilia A [12] . A recent meta-analysis showed a high inhibitor risk for patients with severe hemophilia A carrying large deletions and nonsense variants, a medium risk for those carrying splicing variants and intron 1 and intron 22 inversions, and a low risk for those carrying small deletions/insertions and missense variants [12] . According to the putative degree of gene disruption and the genetically predicted lack of protein synthesis, genetic variants causing hemophilia A have also been classified as null and non-null [13] .
In this study, the role of null and non-null F8 mutations in inhibitor risk was evaluated in a cohort of 231 patients with severe hemophilia A enrolled in the framework of the Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET) study [14] . We also assessed whether or not additional criteria, such as in silico analysis and plasma levels of FVIII antigen (FVIII:Ag), could help to improve the evaluation of inhibitor risk based on the null/non-null classification.
Materials and methods
Patient cohort
All cases analyzed in the present study were previously untreated or minimally treated patients with severe hemophilia A enrolled in the SIPPET study [14] . The patients were randomized 1 : 1 to receive plasma-derived or recombinant FVIII, and followed up to inhibitor development, for 50 exposure days (EDs), or for 3 years, whichever occurred first, or censored when follow-up was shorter.
At screening and before any FVIII exposure, severe deficiency of FVIII:C (< 0.01 IU mL À1 ) and the absence of FVIII inhibitors (≤ 0.4 BU) were verified in patient plasma at the local laboratories, and confirmed at the central laboratory of the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center by means of the one-stage functional assay [15] and the Bethesda assay with the Nijmegen modification [16] . FVIII:Ag levels were measured at screening by enzyme immunoassay with the Asserachrom VIII:Ag kit (Stago, Asni eres sur Seine, France) in all analyzed patients. After the first infusion of an FVIIIcontaining product, inhibitors were evaluated regularly every 2 weeks in patients receiving prophylactic treatment, and every 3-4 EDs during the first 20 infusions, and then every 10 EDs up to 50 consecutive EDs or every 3 months, whichever came first, plus at the final visit in on-demand-treated patients [14] . Positivity for inhibitors (> 0.4 BU) was confirmed twice within 14 days both at local and at central laboratories, and this was followed by monthly tests for the subsequent 6 months.
Detection of mutations in F8
Genomic DNA was extracted from 5 mL of peripheral blood samples collected in EDTA with the standard salting-out method [17] . Mutational scanning of F8 was accomplished with a multistep approach. Detection of intron 22 and intron 1 inversions was performed with long-range PCR, as previously described [18, 19] . Point mutation detection was performed by bidirectional sequencing of amplicons encompassing coding regions, splicing junctions, and 5 0 and 3 0 untranslated regions, as previously reported [20] . Exonic deletions were identified in PCR-negative samples by multiplex ligation-dependent probe amplification (MLPA) with the MLPA P178-A1 kit (MRC-Holland, Amsterdam, the Netherlands), according to the manufacturer's instructions. To rule out duplications, MLPA was also performed in samples negative for inversions and point mutations.
In silico analyses
The deleterious effects of missense variants were assessed with the web-based tools POLYPHEN 
Statistical analysis
Kaplan-Meier survival analyses were performed to assess the cumulative incidence of inhibitors according to mutation groups. Incidence rates were compared by the use of Cox regression survival analyses, and CIs were obtained from this model. Statistical analyses were performed with SPSS, version 23.0 (IBM Corp., Armonk, NY, USA).
Results
Mutational spectrum
Of 251 randomized patients with severe hemophilia A involved in the SIPPET study [14] Comparison of the mutational spectrum in the SIPPET cohort with that reported in a meta-analysis involving 5383 severe hemophilia A patients [12] showed a similar distribution, with nearly half of the patients carrying the intron 22 inversion, and a somewhat higher frequency of nonsense variants and lower frequency of missense variants (Fig. 1A) . Similar results were found when nonredundant alterations listed in the FVIII Variant Database (http://www.factorviii-db.org/) were used (Fig. 1B) . In Indian and Iranian patients, representing 35% and 13% of our cases, the mutation distribution was similar to those in previous reports from those countries [21] [22] [23] .
Nonsense and frameshift variants
Nonsense and frameshift variants were scattered across the entire FVIII protein, and were mainly localized in the large B domain (Fig. 2A,B) . Fourteen nonsense and eight frameshift variants were previously unreported ( Fig. 2A,B) . Nine recurrent variants were found in two or three patients ( Fig. 2A,B) . As it is known that F8 transcripts harbouring premature stop codons escape degradation by nonsensemediated decay [24] , these nonsense and frameshift variants are predicted to cause the synthesis of FVIII proteins with C-terminal truncations ranging from 1.1% (p.Arg2326*) to 99.5% (p.Cys12*), and from 3.3% (p.Met2274Asnfs*79+32) to 97.6% (p.Phe57Serfs*25), respectively ( Fig. 2A,B) . The addition of variable stretches of aberrant amino acids (ranging from two to 111) at the C-terminus can also be predicted for frameshift variants (Fig. 2B ). Taken together, these genetic defects feature a wide spectrum of possible effects on plasma FVIII levels related to the loss of specific FVIII domains.
Traces of FVIII:Ag were detected in two patients carrying the p.Tyr124* and p.Ser1026* nonsense variants (FVIII:Ag 1.4% and 3.2%, respectively) and the p.Ser946Ilefs*5 frameshift variant (FVIII:Ag 2%). Plasma FVIII:Ag was undetectable (FVIII:Ag < 1%) in patients carrying other nonsense and frameshift variants; no plasma samples of patients with p.Arg52*, p.Asn609* and p.Arg1985* were available.
Whereas the disease association of inversions in hemophilia A is well established and that of large deletions and truncating variants is self-explanatory, this is not the case for single or multiple missense and splicing variants. To distinguish deleterious from benign variants according to their predicted pathogenetic role, we performed multiple in silico analyses on all the synonymous and non-synonymous substitutions (i.e. missense variants) (Table 2) , and on the nucleotide substitutions localized in exon-intron boundaries that may affect donor and acceptor splice sites (i.e. splicing variants) ( Table 3 ).
In silico analysis of missense variants
All of the 28 variants listed in Table 2 were analyzed by means of two of the most widely accessed prediction software packages, i.e. POLYPHEN-2 and MUTPRED, which base their prediction on information derived from multiple sequence alignment and the combination of structural (POLYPHEN-2) and functional (MUTPRED) parameters [25] . We also used the recently developed CADD software [26] , which combines a wide range of annotations, including protein level scores (like POLYPHEN-2), functional genomic data, and transcript information. All algorithms indicated disease-causative associations for 17 missense variants, four of them (p.Asn109Asp, p.Pro165Thr, p.Asp561Val, and p.Gly2107Val) not previously reported (Table 2 ; Fig. 2C ). These missense variants were localized in the A1, A2, A3 and C1 FVIII domains, and two of them were found in two patients (Fig. 2C ). POLYPHEN-2 predicted probable deleterious effects for these variants, with the highest score of 1 ( Table 2) . Concerning the MUTPRED output, a high probability of deleterious variants, indicated by a general score ranging from 0.669 to 0.987, was provided along with information on the potential pathogenetic molecular mechanisms and the likelihood of disease association (Table 2) . CADD prediction allocated these variants to the range of the 0.1-1% most harmful substitutions, with scores ranging from 23.5 to 35 (Table 2) . Taken together, these analyses suggest that all of the 17 missense variants are likely to be causative of hemophilia A. Conversely, no pathogenicity was predicted for the p.Arg1740Lys substitution, which is a new and unique genetic variant found in one patient only (Table 2 ).
In addition, no pathogenic effects were predicted for five previously reported polymorphisms and three new variants (p.Ile3Val, p.His1207=, and p.Ser1572=) ( Table 2 ). Possible deleterious effects were predicted for two variants: the new p.Leu882Arg and p.Glu2023Lys, FVIII:Ag, factor VIII antigen level expressed as a percentage (%) of normal plasma level and reported for the missense variants and not (/) for polymorphisms; g, general score; MoRF, Molecular Recognition Features; NA, not available; p, property score; -, no hypotheses regarding the molecular mechanism (g > 0.5 and p > 0.05). *Numbering refers to RefSeq NP_000123.1. Variants previously unreported are in bold. †Numbering refers to RefSeq NM_000132.3. ‡POLYPHEN-2 scores ranging from 0 (most probably benign) to 1 (most probably damaging). §CADD scaled score ranking a variant relative to all possible substitutions of the human genome in order of magnitude terms. Values of ≥ 20 indicate that these are predicted to be the 1% most deleterious substitutions in the human genome. ¶MUTPRED indicates the probability of a deleterious mutation according to the general score (g), information about the possible pathogenetic molecular mechanisms according to the property score (p), and the hypotheses of disease association on the basis of the combination of g and p scores: actionable (g > 0.5 and p < 0.05); confident (g > 0.75 and p < 0.05); and very confident (g > 0.75 and p < 0.01).
p.Thr884Glnfs*7 and p.Ser1676* truncating variants, they are not expected to be the cause of disease in the corresponding patients. Among patients carrying missense variants, 10 had measurable FVIII:Ag levels up to 16.5% (Table 2 ).
In silico analysis of splicing variants
All of the 16 nucleotide variations identified in introns and at the exon-intron junctions were analyzed in silico with the prediction programs SPLICE SITE FINDER-LIKE, MAXENT SCAN, NEURAL NETWORK SPLICE SITE, GENESPLICER, and HU-MAN SPLICING FINDER. Twelve variations that affect the conserved dinucleotides of donor and acceptor splice sites and the fourth and fifth nucleotides of donor splice sites were predicted to cause the disappearance of the corresponding physiological splice sites (Table 3) . They include the unreported c.389-1G>A (found in two patients) and the c.601+2insC, c.670+1G>A, c.766_787+1del, c.1537+1G>T, c.5374-2A>G and c.6115+4delA variants. In only two cases (c.601+2insC and c.1903+5G>A) did some software programs predict weakening of the wild-type splice site instead of its complete abolishment. An additional in silico analysis of these variations, performed with the NET-GENE2 prediction tool, confirmed the disappearance of the physiological splice sites (data not shown). In some cases, the activation of cryptic splice sites around the mutated site was predicted (Table 3 ). In addition to these splicing variants, four intronic variants (including the unreported c.388+76C>T and c.5586+7A>G transitions) were predicted not to affect the wild-type splice sites, and were thus considered to be polymorphisms (Table 3) .
Moreover, effects on transcript processing of nucleotide substitutions affecting the last base of exon 3 (c.388G>T, p.Gly130*; c.388G>A, and p.Gly130Arg) and exon 14 (c.5219G>A and p.Arg1740Lys) were evaluated in silico (Table 3 ; Fig. 2A,C) . In all cases, the predicted weakening or abolishment of the corresponding splice site suggested an alteration of the splicing outcome (Table 3) . Therefore, p.Gly130* can be considered to be a nonsense/ splicing variant, the p.Gly130Arg a missense/splicing alteration, and the new p.Arg1740Gly, previously predicted to be a benign missense variant, a putative causative splicing variant (Table 3) . Among patients carrying splicing variants, four had detectable trace of FVIII:Ag up to 1.6% (Table 3) .
Large deletions
All of the large deletions listed in Table 4 were previously described in patients with severe hemophilia A, four of them having been reported in several patients. In our cohort, 203 patients (87.9%) had FVIII:Ag plasma levels below 1%, and 23 patients (10%) had measurable FVIII: Ag levels ranging from 1% to 16.5%. Among the 16 patients with large deletions, five (31.3%) had small but measurable amounts of plasma FVIII:Ag, ranging from 1.7% to 13.5%. In particular, these patients shared the deletions of exon 6 and of exons 5 + 6 ( Table 4) . As exons 5 and 6 have 69 and 117 nucleotides, respectively, skipping of these exons could cause in-frame deletions and synthesis of FVIII proteins with an A1 domain lacking 39 (exon 6 deletion) and 62 (exon 5 + 6 deletion) amino acids.
Inversions of intron 1 and intron 22
No traces of FVIII:Ag (<1%) were detected in the six patients with inversion of intron 1 or in 108 of 110 patients with inversion of intron 22. Residual traces of FVIII:Ag (1%) were found in one patient carrying the intron 22 inversion, and no plasma sample of the remaining patient was available.
Inhibitor occurrence and type of F8 mutation Seventy-two of 231 patients with a variant identified as causing hemophilia A (31.2%) developed an FVIII inhibitor, with a cumulative inhibitor incidence of 36.3% (95% CI 29.4-43.2) during the 50 EDs of FVIII replacement therapy. In order to evaluate the association between F8 variants and inhibitor development, all of the 231 causative variants were first grouped into low-risk and high-risk mutations according to Gouw et al. [28] (Fig. 3A) . Only a small difference was observed in the cumulative inhibitor incidence (32 (Fig. 3A) .
To evaluate the role of trace amounts of FVIII on immune tolerance to this protein and thus inhibitor incidence, all 231 variants were further classified as null and non-null according to their expected inability or ability to synthesize some dysfunctional FVIII protein, according to the criteria of Carcao et al. [13] (Fig. 3B) . The cumulative inhibitor incidence rates were 38.5% (95% CI 31.1-45.9) for null mutations and 23.8% (95% CI 6.7-40.9) for nonnull mutations, with an HR of 2.01 (95% CI 0.87-4.63) (Fig. 3B) .
The same analysis was taken further on groups of null and non-null mutations reclassified according to their deleteriousness as predicted in silico. In particular, the c.1903+5G>A and c.6115+4delA variations, which failed to affect canonical splice site dinucleotides but were predicted to abolish the physiological ones, the c.388G>A transition, predicted to be either a missense or a splicing variant, and the c.5219G>A nucleotide substitution, predicted to be a splicing variant instead of a missense mutation, were all shifted from the non-null to the nullmutation category (Fig. 3C) . The cumulative incidence of inhibitor development remained approximately similar: 38.2% (95% CI 30.9-45.5) and 24.1% (95% CI 5.1-43.1) for null versus non-null in silico mutation groups, with an HR of 2.08 (95% CI 0.84-5.17) (Fig. 3C ). An additional criterion was applied in order to distinguish the null and non-null mutations according to FVIII:Ag levels. In particular, the 23 variants found in patients with measurable FVIII:Ag levels (≥1%) were reclassified as non-null, and those with undetectable FVIII:Ag (<1%) as null (Fig. 3D) . This led to a larger difference in risk: cumulative incidence rates of 38.3% (95% CI 31.1-45.6) and 10.1% (95% CI 3.0-35.0) for these revised no antigen versus antigen mutation groups, with a high HR of 3.61 (95% CI 0.89-14.74) (Fig. 3D) .
Furthermore, both in silico and antigen criteria were applied together to the original null and non-null classification, and an approximately similar difference in cumulative incidence was found (39.2% [95% CI 31.6-46.8] and 23.0% [95% CI 7.5-38.5] for in silico + antigen null and non-null mutations), with an HR of 2.13 (95% CI 0.97-4.63) (Fig. 3E) .
The cumulative incidence rates were further evaluated with omission of the recurrent inversion of intron 22, which is conventionally deemed to be a detrimental/null mutation. Despite larger CIs, owing to the reduced number of analyzed cases (121 instead of 231 mutations), the HRs for high-risk/null mutations were found to be similar to the previous ones: 1.25 (95% CI 0.64-2.46), 1.93 (95% CI 0.80-4.65), 1.98 (95% CI 0.77-5.12), 3.13 (95% CI 0.75-13.08) and 2.00 (95% CI 0.87-4.58) for Gouw et al. [28] , Carcao et al. [13] , in silico, antigen and in silico + antigen classifications, respectively.
The positive predictive value of a null mutation for inhibitor development was low for all models (33-34%), whereas the negative predictive value was 91% for the antigen model (Fig. 3) .
Discussion
In a cohort of 231 pediatric patients with severe hemophilia A enrolled in the SIPPET study, mutation detection was highly successful (98.3%). This highlights the effectiveness of multistep screening, and suggests the usefulness of probing elusive variants in commonly unexplored deep-intronic regions. As expected, besides the canonical inversions of intron 22 (47.6%) and intron 1 (2.6%), which accounted for appriximately half of all identified causative variants, high allelic heterogeneity was found, as confirmed by the wide mutational spectrum and the high frequency (36%) of previously unreported variants. Moreover, some mutational hot spots were found ( Fig. 2; Tables 3 and 4) , with 13 of 16 recurrent point mutations and deletions (81.3%) being identified in patients from different countries.
According to the fully or partially expected impairment of protein synthesis, mutations are generally classified as null and non-null. However, the damaging effects and the causal role of variants are often predicted rather than experimentally determined. Programs enabling the prediction of the pathogenicity of the genetic variants are widely used, following the generation of massive data from next-generation sequencing [29] . The application of multiple algorithms for sequence variant interpretation may improve prediction [29] . We used multiple computational methods to predict the disease association of missense and splicing variants, allowing us to classify a variant as neutral or causative, and to predict the type of mutation (i.e. missense versus splicing) and the extent of the damage resulting from the splicing variants. Although these tools provide us with a good interpretation of splicing variants, they cannot predict the exact splicing outcomes (i.e. exon skipping, activation of cryptic splice sites, and intron retention), resulting in the synthesis of a varied pattern of aberrant FVIII proteins. Ex vivo approaches, based on the analysis of illegitimate F8 transcripts and in vitro expression of the FVIII mutant proteins, are much more informative than in silico predictions, and can be used to more accurately investigate the consequences of missense or truncating variants [30] [31] [32] . Moreover, breakpoint mapping and transcript analysis should better characterize large deletions involving one or more exons. This is the case for exon 6 and exon 5 + 6 deletions, whose skipping should allow the synthesis of mutant FVIII proteins with in-frame deletions, described herewith in five patients with detectable levels of endogenous FVIII. However, these approaches are laborious and time-consuming, and are therefore not applicable to clinical practice.
To date, the F8 mutation profile is the most promising inhibitor risk predictor in severe hemophilia [12] , and is one of three factors included in the two inhibitor risk prediction models [33, 34] . Furthermore, it is likely that residual amounts of endogenous FVIII in plasma protect patients from the development of alloantibodies. Therefore, the detection of trace amounts of FVIII could improve our insights into the genotype-phenotype association (i.e. F8 mutation type-inhibitor risk association). Up to now, the lack of systematic measurements of immunoreactive FVIII in the plasma of severe hemophilia A patients and of in vitro experimental assays that are able to reveal the real effect of each F8 variant have hampered this evaluation. In order to address these gaps in our knowledge, we collected data on FVIII:Ag and F8 mutation in the SIPPET study patients [14] , and analyzed their associations with inhibitor development. To attain this goal, we chose to cluster the F8 genetic defects into null and non-null mutations, not only according to the expected degree of FVIII synthesis, but also on the basis of in silico prediction of their pathogenic role and plasma levels of FVIII:Ag. In line with previous results, our findings confirm that F8 mutations that are conventionally classified as null are more prone to causing inhibitor development than conventional non-null mutations (HR 2.01; 95% CI 0.87-4.63; Fig. 3B Fig. 3D ), confirming the protective effect of minute amounts of FVIII. The mutation reclassification taking into account both in silico analyses and FVIII:Ag levels did not change the overall predictivity (HR 2.13, but with a narrower CI, i.e. 0.97-4.63; Fig. 3E ).
In addition to the plasma expression of FVIII, the intracellular expression of FVIII observed with inversion of intron 22 has been recently proposed as a mechanism of inhibitor protection [35] . Accordingly, this gene inversion would cause a lower risk of inhibitor formation than other null mutations associated with no secretion of FVIII. However, our exclusion of the intron 22 inversion from all of the described cumulative incidence analyses reduced to half the number of analyzed mutations but failed to affect the results. These findings emphasize the importance of investigating the plasma levels of residual FVIII:Ag for each causative variant in order to really understand its clinical relevance. However, our data are limited by the small sample size, particularly regarding missense and splice site variants and measurable FVIII: Ag, which led to wide CIs. Therefore, more patients with severe hemophilia A should be evaluated in order to strengthen our findings.
A minor limitation of this study concerns the use of a mAb for the FVIII:Ag measurement, which could result in some aberrant FVIII peptides being missed. The use of polyclonal antibodies could probably improve the detection of a trace amount of any circulating FVIII:Ag. Nevertheless, whichever model was used, the predictive power for inhibitor development remained low, indicating the presence of other acquired determinants of inhibitor development. Detection of trace amounts of FVIII in patient plasma proved to have a high negative predictive value, but this concerned only a minority (10%) of patients.
In conclusion, with the aforementioned limitations, the analytical methods employed by us of in-depth investigation of the pathogenic role of F8 mutations may help to better predict the risk of inhibitor development.
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